What is William Blair’s Forecast for VERV FY2024 Earnings?

Verve Therapeutics, Inc. (NASDAQ:VERV) – Stock analysts at William Blair upped their FY2024 earnings per share estimates for Verve Therapeutics in a research note issued to investors on Tuesday, November 5th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($2.32) per share for the year, up from their previous forecast of ($2.41). The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.65) per share. William Blair also issued estimates for Verve Therapeutics’ Q4 2024 earnings at ($0.55) EPS, Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.63) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.67) EPS and FY2025 earnings at ($2.63) EPS.

Verve Therapeutics (NASDAQ:VERV) last announced its earnings results on Tuesday, November 5th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.11. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The firm had revenue of $6.87 million for the quarter, compared to analysts’ expectations of $2.75 million. During the same quarter in the previous year, the business posted ($0.72) EPS. The company’s quarterly revenue was up 120.2% on a year-over-year basis.

A number of other brokerages have also recently commented on VERV. HC Wainwright dropped their price target on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday. Royal Bank of Canada dropped their target price on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Canaccord Genuity Group raised their price target on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $25.75.

Verve Therapeutics Stock Performance

Shares of VERV opened at $6.31 on Friday. Verve Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $19.34. The firm’s 50-day simple moving average is $5.48 and its two-hundred day simple moving average is $5.70. The stock has a market cap of $534.20 million, a PE ratio of -2.59 and a beta of 1.75.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC increased its holdings in Verve Therapeutics by 908.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 7,714 shares of the company’s stock worth $38,000 after buying an additional 6,949 shares in the last quarter. Creative Planning purchased a new position in shares of Verve Therapeutics during the third quarter valued at approximately $50,000. PFG Investments LLC bought a new position in Verve Therapeutics during the third quarter valued at approximately $53,000. Daiwa Securities Group Inc. grew its position in Verve Therapeutics by 89.8% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock worth $59,000 after purchasing an additional 5,723 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new stake in Verve Therapeutics in the 1st quarter worth approximately $191,000. Hedge funds and other institutional investors own 97.11% of the company’s stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.